title: The effects of prucalopride on postoperative ileus in guinea pigs.
abstract: OBJECTIVE
  Postoperative ileus (POI) is an impairment of coordinated gastrointestinal (GI) motility that develops as a consequence of abdominal surgery and is a major factor contributing to patient morbidity and prolonged hospitalization. The aim of this study was to investigate the effects of different 5-hydroxytryptamine 4 (5-HT₄) receptor agonists, which stimulate excitatory pathways, on a POI model.
  
  
  METHODS
  The experimental model of POI in guinea pigs was created by laparotomy, gentle manipulation of the cecum for 60 seconds, and closure by suture, all under anesthesia. Different degrees of restoration of GI transit were measured by the migration of charcoal. Colonic transit was indirectly assessed via measurement of fecal pellet output every hour for 5 hours after administration of various doses of mosapride, tegaserod, prucalopride, and 5-HT.
  
  
  RESULTS
  Charcoal transit assay showed that various 5-HT₄ receptor agonists can accelerate delayed upper GI transit in a dose-dependent manner. However, fecal pellet output assay suggested that only prucalopride had a significant effect in accelerating colonic motility in POI.
  
  
  CONCLUSIONS
  Although mosapride, tegaserod, and prucalopride produce beneficial effects to hasten upper GI transit in the POI model, prucalopride administered orally restores lower GI transit as well as upper GI transit after operation in a conscious guinea pig. This drug may serve as a useful candidate for examination in a clinical trial for POI.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
authors.forename: Soo Jung
authors.initials: SJ
authors.lastname: Park
authors.forename: Eun Ju
authors.initials: EJ
authors.lastname: Choi
authors.forename: Young Hoon
authors.initials: YH
authors.lastname: Yoon
authors.forename: Hyojin
authors.initials: H
authors.lastname: Park
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D001572:Benzofurans / Q000008:administration & dosage / Q000494:pharmacology*; D002606:Charcoal / Q000493:pharmacokinetics; D003106:Colon / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006168:Guinea Pigs; D045823:Ileus / Q000601:surgery*; D007211:Indoles / Q000494:pharmacology; D007813:Laparotomy; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D011183:Postoperative Complications / Q000188:drug therapy; D012701:Serotonin / Q000494:pharmacology; D058828:Serotonin 5-HT4 Receptor Agonists / Q000494:pharmacology*
chemical_list: D001549:Benzamides; D001572:Benzofurans; D007211:Indoles; D009025:Morpholines; D058828:Serotonin 5-HT4 Receptor Agonists; C406662:prucalopride; D002606:Charcoal; D012701:Serotonin; C105050:tegaserod; C062720:mosapride
keywords: 5-HT₄; Postoperative ileus; gastrointestinal transit; prucalopride; receptor agonist